Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 18, Issue 3, 2000, Pages 609-622

  Nemunaitis, J ^a   Swisher, S G ^a   Timmons, T ^a   Connors, D ^a   Mack, M ^a   Doerksen, L ^a   Weill, D ^a   Wait, J ^a   Lawrence, D D ^a   Kemp, B L ^a   Fossella, F ^a   Glisson, B S ^a   Hong, W K ^a   Khuri, F R ^a   Kurie, J M ^a   Lee, J J ^a   Lee, J S ^a   Nguyen, D M ^a   Nesbitt, J C ^a   Perez Soler, R ^a   Pisters, K M W ^a   Putnam, J B ^a   Richli, W R ^a   Shin, D M ^a   Walsh, G L ^a   Roth, J ^a   more..

^a Introgen Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PROTEIN P53;

ADENOVIRUS; ADULT; AGED; ANTIBODY RESPONSE; APOPTOSIS; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FEMALE; FEVER; FOLLOW UP; GENE TRANSFER; HUMAN; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NICK END LABELING; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY;

EID: 0033950285     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.3.609     Document Type: Article

References (92)

1. Parker SL, Tong T, Bolden S, et al: Cancer Statistics. CA Cancer J Clin 47:5-27, 1997
2. Drings P, Vogt-Moykopf I: Pulmonary resection following chemotherapy, in Peters RM, Toledo J (eds): Current Topics in General Thoracic Surgery, Vol 2: Perioperative Care. Amsterdam, the Netherlands, Elsevier, 1992, pp 197-209
3. Roth J, Fossella F, Komaki R, et al: A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 86:673-679, 1994
4. Fischer JR, Manegold C, Bulzebruck H, et al: Induction chemotherapy with and without recombinant human granulocyte colony-stimulating factor support in locally advanced stage IIIA/B non-small cell lung cancer. Semin Oncol 3:20-27, 1994
5. Perez CA, Stanley K, Grundy G: Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung. Cancer 50:1091-1099, 1982
6. Nesbitt JC, Putnam JB, Walsh GL, et al: Survival in early-stage non-small cell lung cancer. Ann Thorac Surg 60:466-472, 1995
7. Herbst RS, Dang NH, Skarin AT: Chemotherapy for advanced nonsmall cell lung cancer. Hematol Oncol Clin North Am 11:473-517, 1997
8. Klastersky J, Sculier JP, Bureau G, et al: Cisplatin vs. cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer. J Clin Oncol 7:1087-1092, 1989
9. Fukuoka M, Takada M, Yokoyama A, et al: Phase II study of gemcitabine for non-small cell lung cancer in Japan. Semin Oncol 24:87-42-87-46, 1997 (suppl 7)
10. Lynch TJ, Kalish L, Strauss G, et al: Phase II study of topotecan in metastatic non-small cell lung cancer. J Clin Oncol 12:347-352, 1994
11. Masuda N, Fukuoka M, Kudoh S, et al: Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulated factor support for advanced lung cancer. J Clin Oncol 12:1833-1841, 1994
12. Abratt RP, Bexwoda WR, Goedhals L, et al: Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small cell lung cancer. J Clin Oncol 15:744-749, 1997
13. Furuse K, Fukuoka M, Kuba M, et al: Randomized study of vinorelbine (VRB) vs. indesine (VDS) in previously untreated stage IIIB or IV non-small cell lung cancer (NSCLC): The Japan Vinorelbine Lung Cancer Cooperative Study Group. Ann Oncol 7:815-820, 1996
14. Masuda N, Fukuoka M, Kudoh S, et al: Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small cell lung cancer. J Clin Oncol 12:90-96, 1994
15. Marchetti A, Buttitta F, Merlo G, et al: p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res 53:2846-2851, 1993
16. Chiba I, Takahashi T, Nau MM, et al: Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 5:1603-1610, 1990
17. Carbone DP, Mitsudomi T, Chiba I, et al: p53 immunostaining positivitiy is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer: A preliminary report of LCSG 871. Chest 106:3775-3815, 1994
18. Xu M, Kumar D, Srinivas S, et al: Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. Hum Gene Ther 8:177-185, 1997
19. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299, 1995
20. Enock T, Norbury C: Cellular responses to DNA damage: Cell-cycle checkpoints, apoptosis and the role of p53 and ATM. Trends Biol Sci 20:426-431, 1995
21. Dameron K, Vopert OV, Tainsky MA, et al: Control of angiogenesis in fibroblast by p53 regulation of thrombospondin-1. Science 265:1582-1584, 1994
22. El-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of the p53 tumor suppression. Cell 75:817-825, 1993
23. Harper JW, Adami GR, Wei N, et al: The p21 CDK-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816, 1993
24. Xiong Y, Hannon GJ, Zhang H, et al: P21 is a universal inhibitor of cyclin kinases. Nature 366:701-704, 1993
25. Harris C, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318-1326, 1993
26. Sidransky D, Mikkelsen T, Schwechheimer K, et al: Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature 355:846-847, 1992
27. Crook T, Vousden KH: Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. EMBO J 11:3935-3940, 1992
28. Ito T, Seyama T, Mixuno T, et al: Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 52:1369-1371, 1992
29. Isobe T, Hiyama K, Yoshida Y, et al: Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection. Jpn J Cancer Res 85:1240-1246, 1994
30. Thor AD, Moore DH II, Edgerton SM, et al: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992
31. Iwaya K, Tsuda H, Hiraide H, et al: Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 82:835-840, 1991
32. Allred DC, Clark GM, Elledge R, et al: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200-206, 1993
33. Quinlan DC, Davidson AG, Summers CL, et al: Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52:4828-4831, 1992
34. Thorlacius S, Borreson AL, Eyfjord JE: Somatic p53 mutations in human breast carcinomas in an Icelandic population: A prognostic factor. Cancer Res 53:1637-1641, 1993
35. Martin HM, Filipe MI, Morris RW, et al: P53 expression and prognosis in gastric carcinoma. Int J Cancer 50:859-862, 1992
36. Hamada M, Fujiwara T, Hizuta A, et al: The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J Cancer Res Clin Oncol 122:360-365, 1996
37. Harris MP, Sutjipto S, Wills KN, et al: Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther 3:121-129, 1996
38. Wills KN, Maneval DC, Menzel P, et al: Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 5:1079-1088, 1994
39. Lesoon-Wood LA, Kim WH, Kleinman HK, et al: Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther 6:395-405, 1995
40. Xu L, Pirollo KF, Chang EH: Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro. Hum Gene Ther 8:467-475, 1997
41. Blagosklonny MV, El-Diry WS: In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Int J Cancer 67:386-392, 1996
42. Zhang W, Alemany R, Wang J, et al: Safety evaluation of AdCMV-p53 in vitro and in vivo. Hum Gene Ther 6:155-164, 1995
43. Nielsen LL, Dell J, Maxwell E, et al: Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther 4:129-138, 1997
44. Nguyen DM, Spitz FR, Yen N, et al: Gene therapy for lung cancer: Enhancement of tumor suppression by a combination of sequential systemic and adenovirus-mediated p53 gene transfer. J Thor Cardiovasc Surg 112:1372-1377, 1996
45. Fujiwara T, Grimm EA, Mukhopadhyay T, et al: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wildtype p53 gene. Cancer Res 54:2287-229, 1994
46. Roth JA, Nguyen D, Lawrence DD, et al: Retrovirus-mediated wildtype p53 gene transfer to tumors of patients with lung cancer. Nat Med 2:985-991, 1996
47. Zhang WW, Fang X, Mazur W, et al: High efficiency gene transfer and high-level expression of wildtype p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1:5-13, 1994
48. Nemunaitis J, Klemow W, Tong A, et al: Prognostic value of K-ras mutations, ras oncoprotein and c-erb B-2 oncoprotein expression in adenocarcinoma of the lung. Am J Clin Oncol 21:155-160, 1998
49. Bartek J: Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J Pathol 169:27-34, 1993
50. Cai DW, Mukhopadhyay T, Liu Y, et al: Stable expression of the wildtype p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum Gene Ther 4:617-624, 1993
51. Cai DW, Mukhopadhyay T, Roth JA: Suppression of lung cancer cell growth by ribozyme-mediated modification of p53 pre-mRNA. Cancer Gene Ther 2:199-205, 1995
52. Mittal S, McDermott MR, Johnson DC, et al: Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a report. Virus Res 28:67-90, 1997
53. Clayman G, El-Naggar A, Lippman S, et al: Adenovirus mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 16:2221-2232, 1998
54. Brandt CD, Kim HW, Vargosko AJ, et al: Infections in 18,000 infants and children in a controlled study of respiration tract disease: Adenovirus pathogenicity in relation to serologic type and illness syndrome. Am J Epidem 90:484-500, 1969
55. Nicholson F: Introduction to adenoviruses: An overview of morphology, classification and epidemiology. Eye 7:1-4, 1993 (suppl 3)
56. Hierholzer JC: Adenoviruses in the immunocompromised host. Clin Mircobiol Rev 5:262-274, 1992
57. Takafuji ET: Simultaneous administration of live, enteric-coated adenovirus types 4, 7, and 21 vaccines: Safety and immunogenicity. J Inf Dis 140:48-53, 1979
58. Smith R: Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 9:1211-1218, 1956
59. Green M, Wold W, Mackey J, et al: Analysis of human tonsil and cancer DNAs and RNAs for DNA sequences of group C (serotypes 1, 2, 5. and 6) human adenoviruses. Proc Natl Acad Sci U S A 76:6606-6610, 1979
60. Englehardt JF, Simon RH, Yang Y, et al: Adenovirus mediated transfer of the CFRT gene to lung of non-human primates: Biological efficacy study. Hum Gene Ther 4:759-769, 1993
61. Simon RH, Engelhardt JF, Yang Y, et al: Adenovirus-mediated transfer of the CFTR gene to lung of non-human primates: Toxicity study. Hum Gene Ther 4:771-780, 1993
62. Yei S, Mittereder N, Wert S, et al: In vivo evaluation of the study of adenovirus-medicated transfer of the human cystic fibrosis transmembrane conductance regulator of cDNA of the lung. Hum Gene Ther 5:731-744, 1994
63. Gomez-Foix AM, Coats WS, Baque S, et al: Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen. J Biol Chem 267:25129-25134, 1992
64. Graham FL, Prevec L: Manipulation of adenovirus vectors, in Murray EJ (ed): Methods in Molecular Biology, Vol 7: Gene Transfer and Expression Protocols. Clifton, NJ, The Humana Press, 1991, pp 109-128
65. Grunhaus A, Horwitz MS: Adenoviruses as cloning vectors. Semin Virol 3:237-252, 1992
66. Stratford-Perricaudet L, Pericaudet M: Gene transfer into animals: The promise of adenovirus, in Cohen-Haguenauer Q, Boiron M (eds): Human Gene Transfer. Paris, France, Editions John Libbery Eurotext, 1991, pp 51-61
67. Stratford-Perricaudet L, Levrero M, Chasse JF, et al: Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum Gene Ther 1:241-256, 1991
68. Rich DP, Couture M, Cardoza LM, et al: Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis. Hum Gene Ther 4:461-476, 1993
69. Rosenfeld MA, Yoshimura K, Trapnell BC, et al: In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68:143-155, 1992
70. Ragot T, Vincent N, Chafey P, et al: Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature 361:647-650, 1993
71. Jaffe HA, Danel C, Longenecker G, et al: Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nature Genet 1:372-378, 1993
72. Le Gal La Salle G, Robert JJ, Bernard S, et al: An adenovirus vector for gene transfer into neurons and glia in the brain. Science 259:988-990, 1993
73. Ghosh-Choudhury G, Haj-Ahmad Y, Brinkely P, et al: Human adenovirus cloning vectors based on infectious bacterial plasmids. Gene 50:161-171, 1986
74. Ginsberg HS, Horswood RL, Chanock RM, et al: Role of early genes in the pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci USA 87:6191-6195, 1990
75. Prince GA, Porter DD, Jenson AB, et al: Pathogenicity of adenovirus type 5 pneumonia in cotton rats (Sigmond hispidus). J Virol 67:101-111, 1993
76. Swisher SG, Roth JA, Nemunaitis J, et al: Adenoviral-mediated p53 gene transfer in advanced non-small cell lung cancer. J Natl Cancer Inst 91:763-771, 1999
77. Bursch W, Paffe S, Putz B, et al: Determination of the length of the histological stages of apoptosis in normal liver and altered hepatic foci of rats in carcinogenesis. (London) 11:847-853, 1990
78. Mitsudomi T, Steinberg SM, Nau MM, et al: P53 gene mutations in non-small cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7:171-180, 1992
79. 5 promote adenovirus internalization but not virus attachment. Cell 73:309-319, 1993
80. 5 selectively promotes adenovirus-mediated cell membrane permeabilization following internalization. J Cell Biol 127:257-264, 1994
81. v integrins for infection. J Virol 68:6811-6814, 1994
82. Gudas JM, Nguyen H, Klein RC, et al: Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigeneic breast epithelial cells. Clin Cancer Res 1:71-80, 1995
83. Bursch W, Kleine L, Tenniswood M: The biochemistry of cell death by apoptosis. Biochem Cell Biol 68:1071-1074, 1990
84. Ueda M, Ueki K, Kumagai K, et al: Apoptosis and tumor angiogenesis in cervical cancer after preoperative chemotherapy. Cancer Res 58:2343-2346, 1998
85. Roth JA: Clinical protocol: Modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin. Hum Gene Ther 7:1013-1030, 1996
86. Fujiwara T, Grimm EA, Mukhopadhyay T, et al: A retroviral wildtype p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 53:4129-4133, 1993
87. Wang J, Bucana CD, Roth JA, et al: Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53. Cancer Gene Ther 2:9-17, 1995
88. Pearson AS, Spitz FR, Swisher SG, et al: Upregulation of the proapoptotic mediators bax and bak following adenovirus-mediated p53 gene transfer in lung cancer cells. Clin Cancer Res (in press)
89. Fujiwara T, Grimm EA, Mukhopadhyay GT, et al: Induction of chemosinsitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wildtype p53 gene. Cancer Res 54:2287-2291, 1994
90. Roth JA, Nguyen D, Lawrence DD, et al: Retrovirus-mediated wildtype p53 gene transfer to tumors of patients with lung cancer. Nat Med 2:985-991, 1996
91. Bouvert M, Ellis LM, Nishizaki M, et al: Adenovirus-mediated wildtype p53 gene transfer downregulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 58:2288-2292, 1998
92. Seth P, Katayose D, Zhuangwu L, et al: A recombinant adenovirus expressing wild type p53 induces apoptosis in drug-resistant human breast cancer cells: A gene therapy approach for drug-resistant cancers. Cancer Gene Ther 4:383-390, 1997